Compare RPID & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPID | STXS |
|---|---|---|
| Founded | 2006 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.3M | 201.6M |
| IPO Year | 2021 | 2004 |
| Metric | RPID | STXS |
|---|---|---|
| Price | $2.50 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $8.00 | $4.00 |
| AVG Volume (30 Days) | 183.1K | ★ 385.7K |
| Earning Date | 03-12-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.78 | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,587,000.00 | $29,346,617.00 |
| Revenue This Year | $21.86 | $34.08 |
| Revenue Next Year | $26.23 | $35.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.74 | N/A |
| 52 Week Low | $1.86 | $1.54 |
| 52 Week High | $4.94 | $3.59 |
| Indicator | RPID | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 29.79 | 33.27 |
| Support Level | N/A | N/A |
| Resistance Level | $3.76 | $2.52 |
| Average True Range (ATR) | 0.31 | 0.12 |
| MACD | -0.20 | -0.02 |
| Stochastic Oscillator | 3.16 | 14.05 |
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.